UBS Group’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-715
| Closed | -$4.49K | – | 10237 |
|
|
2023
Q2 | $4.49K | Buy |
715
+667
| +1,390% | +$4.42K | ﹤0.01% | 7526 |
|
|
2023
Q1 | $182 | Sell |
48
-195
| -80% | -$901 | ﹤0.01% | 9152 |
|
|
2022
Q4 | $803 | Buy |
243
+242
| +24,200% | +$1.11K | ﹤0.01% | 10066 |
|
|
2022
Q3 | $0 | Sell |
1
-764
| -100% | -$3.79K | ﹤0.01% | 11319 |
|
|
2022
Q2 | $4K | Buy |
765
+35
| +5% | +$228 | ﹤0.01% | 9197 |
|
|
2022
Q1 | $7K | Buy |
730
+573
| +365% | +$5.37K | ﹤0.01% | 8888 |
|
|
2021
Q4 | $2K | Buy |
157
+156
| +15,600% | +$2.34K | ﹤0.01% | 9874 |
|
|
2021
Q3 | $0 | Sell |
1
-562
| -100% | -$16.2K | ﹤0.01% | 10334 |
|
|
2021
Q2 | $22K | Buy |
563
+562
| +56,200% | +$24.5K | ﹤0.01% | 7246 |
|
|
2021
Q1 | $0 | Sell |
1
-2
| -67% | -$97 | ﹤0.01% | 9648 |
|
|
2020
Q4 | $0 | Sell |
3
-77
| -96% | -$4.21K | ﹤0.01% | 8916 |
|
|
2020
Q3 | $9K | Buy |
80
+79
| +7,900% | +$10.7K | ﹤0.01% | 6972 |
|
|
2020
Q2 | $0 | Sell |
1
-148
| -99% | -$13.1K | ﹤0.01% | 8491 |
|
|
2020
Q1 | $10K | Buy |
149
+32
| +27% | +$2.89K | ﹤0.01% | 6949 |
|
|
2019
Q4 | $10K | Buy |
+117
| New | +$7.89K | ﹤0.01% | 7307 |
|
UBS Group's LMNL Position: Q3 2023 in Review
UBS Group sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q3 2023, closing a stake of 715 shares — an estimated $4.49K sold.
UBS Group first reported a position in LMNL in Q4 2019 and held it in 15 quarters. The position peaked at $22K in Q2 2021. 1 fund tracked by Wall St. Rank holds LMNL as of Q3 2023.
- UBS Group reported no remaining Liminal BioSciences Inc. Common Shares position as of Q3 2023 after selling out during the quarter.
- UBS Group sold 715 Liminal BioSciences Inc. Common Shares shares in Q3 2023, an estimated $4.49K.
- UBS Group first reported a position in Liminal BioSciences Inc. Common Shares in Q4 2019 and held it in 15 quarters.
- UBS Group's Liminal BioSciences Inc. Common Shares position peaked at $22K in Q2 2021.
- 1 fund tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q3 2023.
Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.